Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

NCT05024019 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

95

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Nimotuzumab

Sponsor

Eye & ENT Hospital of Fudan University